Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options-Reference-Cited by-同舟云学术

Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options

Published:2020-12-01 Issue:12 Volume:36 Page:1054-1058
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Dubé Karine¹,Campbell Danielle M.²³,Perry Kelly E.¹,Kanazawa John T.¹,Saberi Parya⁴,Sauceda John A.⁴,Poteat Tonia⁵,Evans David³

Affiliation:

1. UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

2. Charles R. Drew University of Medicine and Science, Los Angeles, California, USA.

3. Delaney AIDS Research Enterprise (DARE) Community Advisory Board, Los Angeles, California, USA.

4. Division of Prevention Sciences, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco (UCSF), San Francisco, California, USA.

5. Department of Social Medicine, UNC School of Medicine, Chapel Hill, North Carolina, USA.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0107

Reference30 articles.

1. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care

2. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

3. Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient

4. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

5. Long-acting injectable therapy

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system;Implementation Science Communications;2024-08-29

2. “This Is Actually a Really Unique Moment in Time”: Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions—A Qualitative Interview Study in the United States;AIDS Research and Human Retroviruses;2024-08-01

3. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States;AIDS and Behavior;2024-04-10

4. “What Is the Benefit?”: Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV;AIDS Education and Prevention;2023-12

5. The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch;Current HIV/AIDS Reports;2023-09-21